Initial chemotherapy in gliomatosis cerebri

Neurology

Volumn 63, Issue 2, 2004, Pages 270-275

  Sanson, Marc ^a   Cartalat Carel, S ^b   Taillibert, S ^a   Napolitano, M ^a   Djafari, L ^a   Cougnard, J ^a   Gervais, H ^a   Laigle, F ^a   Carpentier, A ^a   Mokhtari, K ^a   Taillandier, L ^c   Chinot, O ^d   Duffau, H ^a   Honnorat, J ^b   Hoang Xuan, K ^a   Delattre, J Y ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ACUTE PANCREATITIS; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONTINUING EDUCATION; DRUG EFFICACY; FEMALE; GLIOMA; GLIOMATOSIS CEREBRI; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 3242748175     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000129985.39973.E4     Document Type: Article

References (34)

1. Lantos PL, Bruner JM. In: Kleihues P, Cavenee W, eds. Gliomatosis cerebri in tumours of the nervous system. Lyon: IARC, 2000:92-93.
2. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with malignant gliomas. Ann Neurol 1990;28:818-822.
3. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994;12:627-642.
4. Ross IB, Robitaille Y, Villemure JG, Tampieri D. Diagnosis and management of gliomatosis cerebri: recent trends. Surg Neurol 1991;36:431-440.
5. Cairncross, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994;12:2013-2021.
6. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
7. Benjelloun A, Delavelle J, Lazeyras F, Dietrich PY. Possible efficacy of temozolomide in a patient with gliomatosis cerebri. Neurology 2001;57:1932-1934.
8. Louis E, Keime-Guibert F, Delattre JY, Sanson M. Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri. Neurology 2003;60:151.
9. Artigas J, Cervos-Navarro J, Iglesias JR, Ebhardt G. Review article. Gliomatosis cerebri: clinical and histological findings. Clin Neuropathol 1985;4:135-148.
10. Balko MG, Blisard KS, Samaha FJ. Oligodendroglial gliomatosis cerebri. Hum Pathol 1992;23:706-707.
11. Cervos-Navarro J, Artigas J, Aruffo C, Iglesias J. The fine structure of gliomatosis cerebri. Virchows Arch 1987;A411:93-98.
12. Couch JR, Weiss SA. Gliomatosis cerebri, report of four cases and review of the literature. Neurology 1974;24:504-511.
13. Del Carpio-O'Donovan R, Korah I, Salazar A, Melançon D. Gliomatosis cerebri. Radiology 1996;198:831-835.
14. Fallentin E, Skriver E, Herning M, Broholm H. Gliomatosis cerebri-an appropriate diagnosis? Case reports. Acta Radiol 1997;38:381-390.
15. Hara A, Sakai N, Yamada H, Tanaka T, Mori H. Assessment of proliferative potential in gliomatosis cerebri. J Neurol 1991;238:80-82.
16. Jennings MT, Frenchman M, Shehab T, et al. Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol 1995;10:37-45.
17. Kandler RH, Smith CML, Broome JC, Davies-Jones GAB. Gliomatosis cerebri: a clinical, radiological and pathological report of four cases. Br J Neurosurg 1991;5:187-193.
18. Nahser HC, Gerhard L, Reinhardt V, Nau HE, Bamberg M. Diffuse and multicentric brain tumors-correlation of histological, clinical and CT appearance. Acta Neuropath 1981;(suppl VII):101-104.
19. Nevin S. Gliomatosis cerebri. Brain 1938;61:170-191.
20. Schober R, Mai JK, Volk B, Wechsler W. Gliomatosis cerebri: bioptical approach and neuropathological verification. Acta Neurochir 1991;113:131-137.
21. Spagnoli MV, Grossman RI, Packer RJ, et al. Magnetic resonance imaging determination of gliomatosis cerebri. Neuroradiology 1987;29:15-18.
22. Cozad SC, Townsend P, Morantz RA, Jenny AB, Kepes JJ, Smalley SR. Gliomatosis cerebri: results with radiation therapy. Cancer 1996;78:1789-1793.
23. Elshaikh MA, Stevens GH, Peereboom DM, et al. Gliomatosis cerebri: treatment results with radiotherapy alone. Cancer 2002;95:2027-2031.
24. Kim DG, Yang HJ, Park IA, et al. Gliomatosis cerebri: clinical features, treatment, and prognosis. Acta Neurochir 1998;140:755-762.
25. Perkins GH, Schomer DF, Fuller GN, Allen PK, Maor MH. Gliomatosis cerebri: improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:1137-1146.
26. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996;46:203-207.
27. Buckner JC, Gesme D, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003;21:251-255.
28. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003;14:1722-1726.
29. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003;21:646-651.
30. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20:2267-2276.
31. Donahue B, Scott CB, Nelson JS, et al. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys 1997;38:911-914.
32. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic and survival in patients with anaplastic oligodendrogliomas. J NatI Cancer Inst 1998;90:1473-1479.
33. Hoang-Xuan K, He J, Huguet S, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumoral progression. Neurology 2001;57:1278-1281.
34. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-845.